New therapies for congenital adrenal hyperplasia

Current Opinion in Endocrinology and Diabetes

Volumn 10, Issue 1, 2003, Pages 32-36

  Speiser, Phyllis W ^a,b,c  

^a Northwell Health   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBENOXOLONE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXAMETHASONE; FLUDROCORTISONE; FLUTAMIDE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID; STEROID 21 MONOOXYGENASE; TESTOLACTONE;

ADRENAL TUMOR; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; CUSHING SYNDROME; GONAD TUMOR; HUMAN; HYPERTENSION; HYPOPHYSIS TUMOR; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IATROGENIC DISEASE; IMPAIRED GLUCOSE TOLERANCE; NONHUMAN; PRENATAL DRUG EXPOSURE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SODIUM BALANCE; STEROID 21 MONOOXYGENASE DEFICIENCY; VIRILIZATION;

EID: 27744498805     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200302000-00005     Document Type: Review

References (25)

1. White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000, 21:245-291. A comprehensive review of the subject.
2. Brosnan PG, Brosnan CA, Kemp SF, et al.: Effect of newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med 1999, 153:1272-1278.
3. Speiser PW, Dupont B, Rubinstein P, et al.: High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985, 37:650-667.
4. Fitness J, Dixit N, Webster D, et al.: Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1999, 84:960-966.
5. Kerrigan JR, Veldhuis JD, Leyo SA, et al.: Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab 1993, 76:1505-1510.
6. Metzger DL, Wright NM, Veldhuis JD, et al.: Characterization of pulsatile secretion and clearance of plasma cortisol in premature and term neonates using deconvolution analysis. J Clin Endocrinol Metab 1993, 77:458-463.
7. Migeon CJ, Wisniewski AB: Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency: growth, development, and therapeutic considerations. Endocrinol Metab Clin North Am 2001, 30:193-206. This issue of the Clinics is entirely devoted to CAH in its many forms.
8. Fukushige J, Shimomura K, Ueda K: Influence of upright activity on plasma renin activity and aldosterone concentration in children. Eur J Pediatr 1994, 153:284-286.
9. Creighton SM, Minto CL, Steele SJ: Objective cosmetic and anatomic outcomes at adolescence of feminising surgery for ambiguous genitalia done in childhood. Lancet 2001, 358:124-125. A sobering examination of results of genital reconstructive surgery.
10. New MI, Carlson A, Obeid J, et al.: Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 2001, 86:5651-5657. The largest published series of prenatal dexamethasone-treated offspring in families at high risk for CAH shows good outcomes, but one must remember that the oldest children are still teenagers.
11. Pang SY, Pollack MS, Marshall RN, et al.: Prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1990, 322:111-115.
12. Chin D, Speiser PW, Imperato-McGinley J, et al.: Study of a kindred with classic congenital adrenal hyperplasia: diagnostic challenge due to phenotypic variance. J Clin Endocrinol Metab 1998, 83:1940-1945.
13. Day DJ, Speiser PW, Schulze E, et al.: Identification of non-amplifying CYP21 genes when using PCR-based diagnosis of 21-hydroxylase deficiency in congenital adrenal hyperplasia (CAH) affected pedigrees. Hum Mol Genet 1996, 5:2039-2048.
14. Speiser PW, Dupont J, Zhu D, et al.: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992, 90:584-595.
15. Seckl JR, Miller WL: How safe is long-term prenatal glucocorticoid treatment? JAMA 1997, 277:1077-1079.
16. New MI: Prenatal treatment of congenital adrenal hyperplasia: the United States experience. Endocrinol Metab Clin North Am 2001, 30:1-13.
17. Pang S, Clark AT, Freeman LC, et al.: Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992, 75:249-253.
18. Merke DP, Keil MF, Jones JV, et al.: Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000, 85:1114-1120.
19. Merke DP, Bornstein SR, Avila NA, et al.: NIH conference: future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002, 135:320-334.
20. Gunther DF, Bukowski TP, Ritzen EM, et al.: Prophylactic adrenalectomy of a three-year-old girl with congenital adrenal hyperplasia: pre- and postoperative studies. J Clin Endocrinol Metab 1997, 82:3324-3327.
21. Gmyrek GA, New MI, Sosa RE, et al.: Bilateral laparoscopic adrenalectomy as a treatment for classic congenital adrenal hyperplasia attributable to 21-hydroxylase deficiency. Pediatrics 2002, 109:E28.
22. Meyers RL, Grua JR: Bilateral laparoscopic adrenalectomy: a new treatment for difficult cases of congenital adrenal hyperplasia. J Pediatr Surg 2000, 35:1586-1590.
23. Warinner SA, Zimmerman D, Thompson GB, et al.: Study of three patients with congenital adrenal hyperplasia treated by bilateral adrenalectomy. World J Surg 2000, 24:1347-1352.
24. Van Wyk JJ, Gunther DF, Ritzen EM, et al.: The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996, 81:3180-3190.
25. Tajima T, Okada T, Ma XM, et al.: Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochrome P450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice. Gene Ther 1999, 6:1898-1903.